Tau is a microtubule-associated protein that normally stabilizes the internal scaffolding of neurons. In Alzheimer’s disease and a family of related disorders collectively termed tauopathies, tau detaches from microtubules, misfolds, and polymerizes into paired helical and straight filaments that populate neurofibrillary tangles. For decades, these filaments were viewed through the lens of light and conventional electron microscopy, which revealed their overall morphology but not the atomic contacts that hold them together. The advent of cryo-electron microscopy changed that. By freezing thousands of filament samples in vitreous ice and computationally averaging images of countless molecular copies, researchers have resolved the ordered cores of tau filaments from Alzheimer’s disease, chronic traumatic encephalopathy, corticobasal degeneration, Pick’s disease, and several rarer conditions, each with a distinct fold.

These structures established a powerful principle: the fold of the filament core acts as a molecular signature of disease. Alzheimer’s disease tau filaments adopt one characteristic cross-beta architecture, while the filaments of other tauopathies adopt different folds, even though the tau protein sequence is the same. The core, however, is only part of the story. Large regions of the tau molecule remain disordered and invisible in cryo-EM maps, and the filaments carry a dense cargo of post-translational modifications, including phosphorylation, acetylation, truncation, and ubiquitination, many of which sit outside the resolved core. Whether these peripheral modifications merely decorate the filament or actively participate in determining its structure has been an open question.

The new work addresses this question directly by comparing tau filaments from Alzheimer’s disease with those from vacuolar tauopathy, a rare and recently characterized neurodegenerative condition marked by vacuolar changes in the brain and abundant tau inclusions. Using cryo-electron microscopy, the researchers determined the structures of tau filaments extracted from the brains of affected individuals, and then examined how these filaments behave in biological systems. A central result of the study is that tau fibrils from Alzheimer’s disease and from vacuolar tauopathy exhibit distinct seeding patterns in vivo. In other words, when these two types of filaments act as templates for the recruitment of soluble tau, they do not induce the same downstream aggregation behavior, indicating that their structural differences carry functional consequences for the propagation of pathology.

The most surprising structural insight concerns polyubiquitin. Tau filaments in many tauopathies are heavily ubiquitinated, a modification generally interpreted as a cellular tagging system that marks aggregates for degradation by the proteasome or for clearance by autophagy. In the filaments of vacuolar tauopathy, the researchers found that polyubiquitin chains are positioned differently relative to the filament core than in Alzheimer’s disease filaments. Crucially, this repositioning of polyubiquitin is associated with a shift in the protofilament interface, the set of contacts through which the two protofilaments that make up the fibril grip one another. A change at this interface means a change in the overall fold of the filament, altering which tau residues face the solvent and which are buried in the interior of the assembly.

This observation carries significant mechanistic weight. It demonstrates that a covalent modification attached outside the ordered core can exert enough structural influence to remodel the core itself. The polyubiquitin chains, though not part of the cross-beta spine, appear to constrain or redirect how protofilaments associate, effectively selecting an alternative filament fold. From a structural biology standpoint, this expands the concept of the tau filament from a self-determined protein polymer to a composite assembly whose architecture depends on both the tau sequence and the modifications it accrues in the diseased brain. The ordered core and its peripheral cargo are not independent; they are structurally coupled.

The in vivo seeding experiments reinforce the biological relevance of these structural differences. Seeding refers to the ability of an aggregate to template the misfolding of soluble tau, and it underlies the stereotyped spread of tau pathology through the brain along neural connections. If Alzheimer’s disease and vacuolar tauopathy filaments seed differently in living tissue, then the structural variants identified by cryo-EM are not laboratory curiosities but determinants of how disease propagates. Distinct folds may preferentially recruit distinct tau conformations, replicate with different efficiencies, or encounter different barriers to cellular uptake and intercellular transmission. This provides a structural framework for understanding why different tauopathies follow different clinical and pathological courses despite sharing the same aggregating protein.

The findings also have implications for therapeutic development. Several experimental treatments for Alzheimer’s disease and related disorders aim to clear tau aggregates or block their seeding, including immunotherapies with anti-tau antibodies and small molecules designed to stabilize non-pathogenic tau conformations. If the pathological filament structure varies between diseases, and even between molecular subpopulations within a single disease depending on ubiquitination state, then therapies will need to account for this structural heterogeneity. An antibody or inhibitor optimized against the Alzheimer’s disease filament fold may bind poorly to the vacuolar tauopathy fold, and vice versa. Conversely, the exposed polyubiquitin chains themselves could represent disease-specific epitopes or drug targets, offering a way to selectively recognize or destabilize particular filament variants.

More broadly, the study contributes to an evolving view of neurodegenerative disease in which the structural strain of an aggregate, not merely the identity of the aggregating protein, defines the disease entity. This concept, sometimes described as the prion-like strain hypothesis, has gained support from the growing catalogue of distinct filament folds resolved by cryo-EM across amyloid-beta, alpha-synuclein, and TDP-43 aggregates as well as tau. The demonstration that polyubiquitin repositioning can shift the protofilament interface adds a new layer to this framework: the strain landscape is not only diverse but malleable, shaped by the cellular environment and the modification state of the protein. Changes in the ubiquitin-proteasome system that accompany aging or disease could therefore, in principle, nudge tau filaments between alternative structural states.

Many questions remain. The precise atomic details of how polyubiquitin contacts the filament surface and transmits its influence to the protofilament interface will require further high-resolution analysis, and it is not yet clear whether similar modification-driven remodeling occurs in other tauopathies or in filaments carrying other modifications such as phosphorylation. It also remains to be determined whether repositioned polyubiquitin alters filament stability, clearance rates, or interactions with cellular quality-control machinery. Nevertheless, the central conclusion stands on firm ground: modifications outside the ordered core can remodel tau fibril ultrastructure, and the resulting structural variants seed differently in vivo. For a field that has long treated pathological filaments as static end products of neurodegeneration, the message is that these assemblies are dynamic, environmentally responsive structures whose architecture is written jointly by the protein sequence and the cell’s modification machinery. Understanding that interplay may prove essential for diagnosing tauopathies accurately and for designing interventions that target the right molecular shape in the right disease.

Subject of Research: Structural remodeling of pathological tau filaments by polyubiquitin repositioning in Alzheimer's disease and vacuolar tauopathy

Article Title: Repositioning of polyubiquitin alters the pathologic tau filament structure

Article References: Watanabe, R., Creekmore, B. C., Darwich, N. F., Smith, C. L., Xu, H., Baltazar, A., Salphati, S., Changolkar, L., Hoxha, K., Zhang, B., O’Rourke, C. M., Burslem, G. M., Lee, V. M.-Y., Chang, Y.-W., & Lee, E. B. (2026). Repositioning of polyubiquitin alters the pathologic tau filament structure. Nature Structural & Molecular Biology. https://doi.org/10.1038/s41594-026-01879-4

Image Credits: AI Generated

DOI: 10.1038/s41594-026-01879-4

Keywords: tau filaments, polyubiquitin, cryo-electron microscopy, Alzheimer's disease, vacuolar tauopathy, protofilament interface, neurodegeneration, seeding, post-translational modification, protein aggregation, amyloid strains, structural biology

The synaptotagmin family consists of seventeen membrane-associated regulators in mammals, each characterized by a short N-terminal transmembrane region and two cytoplasmic C2 domains that bind calcium with widely varying affinities. This heterogeneity is central to the review’s framework. Only a subset of isoforms functions as conventional fast calcium sensors; several others possess atypical or incomplete calcium-binding sites and appear to perform roles that do not depend on calcium triggering at all, such as membrane trafficking control, receptor turnover, and stress-response signaling. The authors organize the family by function, distinguishing rapid-release sensors such as SYT1, SYT2, and SYT9 in defined neuronal populations, activity-dependent and astrocytic secretion mediated by SYT4, asynchronous release and synaptic dynamics governed by SYT7, and a broader group including SYT3, SYT10, SYT11, SYT13, and SYT17 that connects membrane dynamics to trafficking, proteostasis, and neuronal resilience.

SYT1 remains the archetype. Embedded in synaptic vesicle membranes, it clamps the SNARE fusion machinery until an action potential delivers a pulse of calcium into the presynaptic terminal, at which point its C2 domains insert into membrane phospholipids and drive fast synchronous release. Human mutations in SYT1 produce a severe neurodevelopmental syndrome marked by intellectual disability, hypotonia, and epileptic activity, illustrating how a single point of failure in the fusion apparatus can derail brain development as a whole. The review also highlights emerging translational evidence around SYT1: proteins released from damaged synapses can be detected in cerebrospinal fluid, and SYT1 has been proposed as a candidate biomarker of synaptic injury. The authors are careful to frame this as promising but not yet clinically validated, a distinction that matters in a field where biomarker enthusiasm frequently outpaces reproducibility.

Where SYT1 mediates the lightning-fast synchronous component of neurotransmission, SYT2 and SYT9 handle fast release in specific neuronal populations, including circuits of the neuromuscular junction and specialized sensory pathways. Defects in these isoforms link directly to congenital myasthenic syndromes and neuromuscular junction disease, where the reliability of transmitter release determines whether muscle fibers receive adequate activation. SYT7, by contrast, shapes asynchronous release and vesicle recycling kinetics, fine-tuning the temporal structure of synaptic signaling and supporting forms of synaptic plasticity that depend on residual calcium. SYT4 occupies yet another niche, regulating activity-dependent secretion not only in neurons but also in astrocytes, thereby coupling neuronal activity to glial signaling and to the release of factors such as brain-derived neurotrophic factor that consolidate long-term synaptic change.

The review’s most distinctive contribution may be its treatment of the less glamorous isoforms. SYT3, located predominantly on the presynaptic plasma membrane rather than on vesicles, participates in activity-dependent bulk endocytosis and in the retrieval of synaptic vesicle components after intense stimulation. The authors describe preclinical intervention evidence suggesting that modulating SYT3-dependent endocytosis can protect synapses under metabolic stress, positioning the protein as a candidate therapeutic node. SYT13 likewise emerges from preclinical studies as a neuroprotective factor, with experimental manipulation of its expression influencing neuronal survival pathways, although the authors emphasize that such findings remain at the bench rather than the bedside.

SYT11 occupies a particularly compelling position at the intersection of membrane trafficking and protein quality control. The review identifies SYT11 as a Parkinson’s disease-related trafficking and proteostasis node, connecting vesicular transport, lysosomal function, and the cellular stress responses that determine whether damaged proteins are cleared or accumulate. Given that lysosomal dysfunction and protein aggregation are central themes in Parkinson’s pathology, a synaptotagmin isoform that participates in lysosomal exocytosis and autophagic flux offers a mechanistic bridge between two research literatures that have historically run in parallel. SYT10, expressed notably in the suprachiasmatic nucleus and involved in neurotrophin trafficking, and SYT17, associated with palmitoylation-dependent membrane association and stress signaling, round out a picture of a family whose roles extend deep into the glial and homeostatic dimensions of nervous system biology.

Human genetics, the authors acknowledge, provides comparatively limited direct evidence for some of these connections. The clearest clinical signal involves SYT14, where human genetic data link the isoform to an ataxic phenotype, consistent with its expression in Purkinje cells and its role in spinocerebellar neurodegeneration. For many other family members, the disease associations rest on animal models, cellular studies, and correlative human data rather than definitive Mendelian mutations. The review is notable for its evidence-stratified approach: the authors explicitly separate fast-release sensors with robust genetic and biophysical support, trafficking and proteostasis isoforms supported largely by preclinical work, and biomarker candidates whose clinical utility remains unproven. This candor about the strength of evidence is itself a contribution, offering a roadmap for where the field most urgently needs validation.

Unifying these strands is the concept of neuronal vulnerability. The authors propose a cellular and molecular framework in which synaptotagmin dysfunction destabilizes four interlocking processes: precise membrane fusion, vesicular trafficking and receptor turnover, proteostasis, and stress-response signaling. Because neurons are post-mitotic and metabolically demanding, they tolerate disruption of these processes poorly. Calcium-permeable AMPA receptor insertion, calmodulin-dependent signaling, and the balance between long-term potentiation and synaptic depression all depend on the regulated exo-endocytic cycle that synaptotagmins help orchestrate. When that cycle falters, excitotoxic signaling rises, receptor remodeling goes awry, and the neuron’s capacity to buffer stress erodes, linking a molecular defect in vesicle biology to the slow attrition of neural circuits observed in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis.

The translational implications are carefully hedged but genuinely intriguing. Beyond the SYT1 cerebrospinal fluid biomarker candidate and the preclinical interventions targeting SYT3 and SYT13, the review raises the possibility of adeno-associated virus-based gene approaches and small-molecule modulation of calcium-dependent membrane insertion as future therapeutic strategies, while stressing that none has reached clinical validation. The authors also note the relevance of synaptic vesicle glycoprotein 2A, a target of existing antiepileptic drugs and a widely used PET imaging marker of synaptic density, as a benchmark for how synaptic proteins can become clinically actionable. Whether synaptotagmins will follow that path depends on filling the gaps between biophysical mechanism, animal disease models, and human cohorts.

What emerges from this synthesis is a portrait of the synaptotagmin family as a systems-level regulator of nervous system health rather than a collection of interchangeable calcium sensors. From the millisecond choreography of vesicle fusion to the years-long trajectory of neurodegeneration, these proteins occupy decision points where membrane dynamics meet cellular survival. As the authors conclude, synaptotagmin dysfunction links membrane dynamics, synaptic instability, receptor remodeling, and stress-response failure into a coherent pathway toward neuronal vulnerability. For researchers hunting the molecular roots of neurological disease, that framework reframes an old question, how neurons communicate, into an urgently contemporary one: how the same machinery that transmits the mind can, when it breaks, break the neuron itself.

Subject of Research: Synaptotagmin family proteins and their roles in synaptic vesicle fusion and neurological disorders

Article Title: Synaptotagmin family proteins in neurological disorders: from synaptic vesicle fusion to neuronal vulnerability

Article References: Cui, J., He, J., Su, K., Luo, X., Wang, Z., Song, F., & Zhang, M. (2026). Synaptotagmin family proteins in neurological disorders: from synaptic vesicle fusion to neuronal vulnerability. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06446-0

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06446-0

Keywords: synaptotagmin, synaptic vesicle fusion, C2 domains, SNARE complex, neurodegeneration, SYT1, Parkinson's disease, lysosomal exocytosis, synaptic plasticity, neurodevelopmental disorder, family, proteins

CLN3 Batten disease, formally known as juvenile neuronal ceroid lipofuscinosis, is the most common form of a family of inherited lysosomal storage disorders and affects roughly one in 100,000 live births worldwide. It is caused by mutations in the CLN3 gene, with approximately 85 percent of patients carrying the same genetic defect: a deletion of about one kilobase of DNA that removes exons 7 and 8. Children with the disease typically develop normally until between the ages of four and twelve, when vision loss begins. That vision loss progresses to blindness, followed by cognitive decline, motor deterioration, seizures and brain atrophy, culminating in premature death between the ages of 15 and 30. At the cellular level, the disease is marked by the buildup of autofluorescent storage material inside cells, whose major protein component is subunit C of the mitochondrial ATP synthase enzyme, a molecular fingerprint of failing cellular housekeeping.

The CLN3 protein itself is a transmembrane protein that resides primarily in endosomes and lysosomes, the cell’s recycling and degradation compartments, and although it has been linked to cellular homeostasis and neuronal survival, its precise function has remained elusive. For decades, research into the disease has been dominated by a neuron-centric view, focused on the nerve cells that die as the disease progresses. But an accumulating body of evidence has challenged that framing. Studies in mouse models have shown that glial activation precedes the loss of neurons, and that the locations where glial cells become activated accurately predict where neurons will subsequently die. Even more strikingly, laboratory co-culture experiments have demonstrated that glial cells lacking functional CLN3 are toxic to both healthy and mutant neurons, while adding healthy glial cells to mutant neurons largely rescues their survival. In other words, the supportive cells of the brain may be active participants in the neurodegeneration rather than innocent bystanders.

To interrogate the role of astrocytes specifically, the team took skin biopsy fibroblasts from a Norwegian CLN3 patient homozygous for the canonical 1 kb deletion and reprogrammed them into induced pluripotent stem cells using a Sendai virus-based reprogramming kit. Those pluripotent cells were then guided through a carefully choreographed differentiation pipeline: first into neural stem cells using small molecule inhibitors including CHIR99021 and SB431542, then into glial progenitor cells nourished with FGF-2 and EGF, and finally into mature astrocytes driven by leukemia inhibitory factor, EGF and ciliary neurotrophic factor over a maturation period of four weeks. The resulting cells expressed a suite of astrocyte markers — GFAP, S100β, ALDH1L1 and the glutamate transporter EAAT1/GLAST — at levels confirming successful and pure differentiation, while neuronal and oligodendrocyte markers remained minimal. Quantitative PCR confirmed the patient cells carried two mutated CLN3 alleles, and targeted mass spectrometry revealed that the truncated mutant CLN3 protein was not detectable at all in patient-derived cells, confirming that the deletion effectively abolishes CLN3 protein production.

With a validated cellular model in hand, the researchers performed an integrated analysis of both the transcriptome, using whole-transcriptome RNA sequencing, and the proteome, using label-free quantitative mass spectrometry on a timsTOF Pro 2 instrument in PASEF mode. The scale of the effort was considerable: multiple clones from two healthy control individuals and from the patient, each differentiated in triplicate, generated thousands of differentially expressed genes and proteins that could be compared across the developmental trajectory from stem cell to astrocyte. Gene set enrichment analysis of these datasets revealed the study’s central surprise. While conventional wisdom held that CLN3 loss should primarily disrupt lysosomal function, the young astrocytes showed only subtle lysosomal alterations. The lysosomal marker LAMP1 was present at similar levels in patient and control cells, and processes related to lysosomal protein catabolism were enriched to a similar degree in both genotypes during differentiation.

The mitochondrial story was entirely different, and it unfolded in two distinct phases. In the patient’s induced pluripotent stem cells, gene expression data showed underrepresentation of the mitochondrial respiratory chain complex I, accompanied by signatures of negative regulation of TORC1, a master growth and metabolism regulator — a combination previously observed in yeast models lacking the CLN3 homologue. But when the cells matured into astrocytes, the pattern inverted dramatically: proteins belonging to respiratory chain complexes I and IV, including NADH dehydrogenase components and the mitochondrial respirasome, were significantly overrepresented in the patient-derived cells. This contrasts sharply with the downregulation of these same complexes typically observed in CLN3-deficient neurons. Mitochondrial DNA copy number measurements confirmed that the patient astrocytes did not simply contain more mitochondria; instead, they appeared to pack more respiratory supercomplex proteins into their inner mitochondrial membranes, which themselves showed signs of disorganized structure, with genes governing mitochondrial fusion and inner membrane organization downregulated.

This mitochondrial upheaval rippled into lipid metabolism. The team found elevated levels of ELOVL1, the enzyme responsible for elongating very-long-chain saturated fatty acids, suggesting a shift toward production of longer saturated lipid species — a potentially dangerous change, given that elevated ELOVL1 activity has been linked to neurotoxicity in reactive astrocytes through saturated lipid production. At the same time, ELOVL5 levels dropped slightly, implying reduced synthesis of polyunsaturated fatty acids that maintain membrane fluidity. Fatty acid synthesis enzymes such as ACACA and FASN were downregulated, while the β-oxidation enzymes ACOX1 and ACADVL were upregulated, pointing to a metabolic pivot away from lipid construction and toward fatty acid burning. Notably, ACADS, which handles short-chain fatty acid oxidation and is normally upregulated during healthy astrocyte differentiation, failed to rise in the patient cells, suggesting the metabolic adaptation itself was broken. Because astrocytes account for the oxidation of free fatty acids that represents roughly 20 percent of the brain’s total energy expenditure, these defects strike at the heart of cerebral energy economics.

The dysregulated fat metabolism and aberrant respiratory chain activity came with a third signature: an intensified oxidative stress response. Levels of glutathione synthetase, which produces the cell’s principal antioxidant, were substantially increased in patient cells, as were the glutathione-conjugating enzymes GSTK1 and GSTZ1, along with catalase, NQO1 and the mitochondrial superoxide dismutase SOD2. The researchers interpret this as a compensatory counterattack against elevated reactive oxygen species generated by runaway peroxisomal β-oxidation — ACOX1 activity produces hydrogen peroxide as a byproduct — combined with impaired detoxification of partially oxidized fatty acid intermediates. Prior studies have documented increased oxidative stress in CLN3 lymphoblasts and fibroblasts, and work in fruit flies has shown that CLN3 loss increases vulnerability to oxidative damage while CLN3 overexpression confers resistance, lending independent support to the connection the Norwegian team has now drawn in human astrocytes.

Beyond metabolism, the analysis surfaced evidence of deeper epigenetic rewiring. A multifactorial statistical analysis disentangling the effects of genotype and cell type identified 363 genes whose expression patterns diverge specifically in the patient during astrocyte differentiation, with significant overrepresentation of genes involved in histone H3 and H4 lysine methylation. In patient cells, chromatin-related terms associated with open, transcriptionally active states — such as binding of acetylated histones — were underrepresented, while repressive machinery, including polycomb group complexes and heterochromatin-associated terms, was upregulated. The authors suggest this reflects a global shift toward a more compacted, transcriptionally restrictive chromatin landscape, potentially locking developing astrocytes into aberrant functional states. Additional dysregulation was seen in extracellular matrix genes involved in remodeling, synaptic support and neuroinflammatory signaling, hinting that mutant astrocytes undergo a reactive transformation that could compromise their support of neurons even before overt cell death begins.

The study is not without limitations, which the authors acknowledge candidly. All patient-derived material came from a single individual, so some observed phenotypes could reflect that patient’s unique genetic background rather than CLN3 loss alone, and extending the work to additional patient lines or gene-corrected isogenic controls would strengthen the conclusions. Nevertheless, the findings carry significant therapeutic implications. If mitochondrial dysfunction in astrocytes indeed precedes the lysosomal breakdown that defines advanced disease, then interventions aimed at restoring mitochondrial health — improving respiration, normalizing lipid metabolism, or bolstering antioxidant capacity — could preserve astrocyte function, and through it neuronal survival, potentially delaying disease progression. The team proposes that future work in more complex human models, such as brain organoids incorporating multiple cell types, should be used to establish the precise temporal relationship between astrocytic mitochondrial failure and neuronal death. Because mitochondrial dysfunction is a common thread linking Alzheimer’s, Parkinson’s, Huntington’s and ALS, insights from this rare pediatric disease may ultimately illuminate mechanisms of far more common neurodegenerative conditions, including those associated with aging, underscoring once again that understanding rare diseases can pay dividends well beyond the patient communities they directly affect.

The review, published in the Current Neuroscience Journal by Priyanka Yadav, Dinesh Kumar, Anil Kumar, and corresponding author Sumit Kumar, maps the molecular chain of events through which oxidative stress drives the destruction of nerve cells. Drawing together evidence across five major neurological conditions — Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and epilepsy — the authors make a case that is both sobering and constructive: oxidative stress is not a single entity that can be neutralised with a single pill, but a family of disease-specific chemical processes that demand precision-targeted interventions.

At modest levels, reactive oxygen species are not merely harmless; they are essential. They participate in nerve cell signalling, help sculpt the synaptic connections that underlie learning and memory, and support immune responses within brain tissue. The trouble begins when production outpaces the brain’s capacity for neutralisation, a state scientists call oxidative stress. Because neurons are rich in the polyunsaturated fatty acids that reactive molecules attack most readily, and because the brain maintains comparatively weak antioxidant defences relative to other organs, it is uniquely vulnerable to this kind of chemical damage. Once stress becomes sustained, the consequences cascade: fatty cell membranes are peroxidised, proteins are corrupted and lose their function, DNA strands accumulate lesions, mitochondrial energy machinery falters, chronic inflammation takes hold in brain tissue, and misfolded proteins begin to aggregate into the abnormal clumps that define several neurodegenerative diseases.

What makes the review particularly valuable is its insistence on mechanistic specificity. All five diseases share a common foundation — failing mitochondria, weakened antioxidant defences, excitotoxic excess at synapses, chronic low-grade neuroinflammation, and the accumulation of proteins the cell cannot clear. But the specific chemical routes by which oxidative stress inflicts damage diverge dramatically, and those differences have profound implications for therapy.

Consider Parkinson’s disease, a condition defined by the death of dopamine-producing neurons. Dopamine itself is a chemically restless molecule. Its normal metabolic breakdown generates reactive quinones — dopamine quinones — that are directly toxic to the very neurons that manufacture the neurotransmitter. The result is a self-reinforcing cycle of destruction: the more dopamine is metabolised, the more toxic byproducts accumulate, and the fewer healthy neurons remain to handle the load. Any antioxidant strategy for Parkinson’s that ignores this dopamine-specific chemistry is, the authors suggest, unlikely to succeed.

In amyotrophic lateral sclerosis, the story unfolds differently. Mutations in the SOD1 gene, which encodes one of the cell’s most important antioxidant enzymes, produce a misfolded protein that is not merely inactive but actively poisonous. This corrupted enzyme disrupts redox balance with particular specificity in motor neurons — the large, metabolically demanding cells that control voluntary movement — helping explain why ALS devastates movement while leaving cognition and sensation comparatively intact for much of the disease course.

Alzheimer’s disease presents yet another mechanism. The amyloid-beta fragments that accumulate into the disease’s characteristic plaques act as catalysts for redox-active metal ions such as copper and iron. In the presence of these metals, amyloid-beta drives the generation of highly reactive hydroxyl radicals, producing sharply localised oxidative damage in the immediate vicinity of plaques. Oxidative stress in Alzheimer’s is thus not a diffuse background phenomenon but a concentrated chemical assault, orchestrated in part by the very protein aggregates considered hallmarks of the disease.

Huntington’s disease adds a fourth variant. The mutant huntingtin protein physically impairs mitochondrial function, choking off energy supply and simultaneously increasing the generation of oxidative byproducts. This double blow falls hardest on the striatum, the brain region most affected by the disease, providing a mechanistic explanation for the movement disorders and cognitive decline that characterise the condition. Epilepsy, meanwhile, illustrates how oxidative stress and excitotoxicity feed each other: excessive neuronal firing generates reactive species, which in turn damage the cellular machinery that normally restrains excitability.

The review also devotes careful attention to how oxidative damage is actually measured, an issue of more than academic interest. Researchers rely on a panel of biomarkers: F2-isoprostanes and malondialdehyde as indicators of lipid peroxidation, protein carbonyls and 3-nitrotyrosine as markers of protein oxidation, and 8-hydroxy-2′-deoxyguanosine as evidence of DNA damage. Crucially, the authors draw a conceptual distinction between oxidative stress — the imbalance between production and defence — and oxidative damage, the measurable molecular harm that results. A cell can be under significant stress without yet showing damage if its defences are compensating, and a treatment that reduces one without addressing the other may produce encouraging biomarker readings while failing to change the disease’s trajectory.

This distinction feeds directly into the review’s most provocative argument: an explanation for why antioxidant therapies have so consistently disappointed in clinical trials. Despite decades of compelling laboratory evidence linking oxidative stress to neurodegeneration, broad-spectrum antioxidants have repeatedly failed to deliver meaningful benefits to patients. The authors identify several reasons. Antioxidant drugs must cross the blood-brain barrier in sufficient concentrations, a formidable pharmacological obstacle. Many act at the wrong point in the damage cascade or against the wrong reactive species. Preclinical disease models frequently fail to capture the complexity and chronicity of human neurodegeneration, producing results that simply do not translate.

But the deepest problem may be conceptual. Reactive oxygen species are not waste products to be eliminated; they are signalling molecules woven into the normal fabric of brain function. Indiscriminately suppressing their production risks disrupting the very cellular processes a therapy is meant to protect. A blunt chemical hammer, in other words, cannot fix a system that depends on precisely calibrated chemistry.

The path forward, the authors argue, requires abandoning the shotgun approach. Future therapies should target the specific oxidative pathways relevant to each disease — dopamine quinones in Parkinson’s, SOD1 misfolding in ALS, metal-catalysed oxidation in Alzheimer’s, mitochondrial impairment in Huntington’s — and must be deployed at the appropriate stage of disease progression and within the appropriate cellular compartment. Timing matters as much as target: intervening after decades of accumulated damage may be futile even with the right molecule. Equally important is the smarter use of oxidative damage biomarkers in clinical trials, both to identify the patients most likely to benefit from antioxidant interventions and to verify that a treatment is genuinely reducing oxidative stress in the brain rather than merely performing well on surrogate measures.

For the tens of millions of people worldwide living with these five conditions, and for whom disease-modifying treatments remain painfully elusive, the review offers neither a cure nor a quick breakthrough. What it offers instead is something arguably more valuable at this stage: a coherent mechanistic framework that explains past failures and charts a disciplined route toward therapies that treat oxidative stress not as a generic enemy to be eradicated, but as a set of distinct, disease-specific vulnerabilities to be precisely addressed. In the difficult terrain of neurodegeneration, that kind of clarity may prove to be the most powerful medicine of all.

The Flemish mutation is an A692G substitution in the gene encoding the amyloid precursor protein, or APP. When APP is processed, the change corresponds to an A21G substitution within amyloid-β, the short peptide that aggregates into the plaques characteristic of Alzheimer’s disease. Carriers of this mutation develop a rare, early-onset form of the disease with two unusual pathological hallmarks: pronounced cerebral amyloid angiopathy, in which amyloid accumulates in the walls of cerebral blood vessels, and senile plaque cores that are unusually large. Affected individuals suffer from both progressive dementia and cerebral hemorrhages, a combination that distinguishes the Flemish variant from more common presentations of familial Alzheimer’s disease. Until now, the molecular reason for this vascular tropism remained obscure.

To understand the structural consequences of the mutation, the team turned to cryo-electron microscopy, a technique that images flash-frozen biological molecules at near-atomic resolution and has in recent years transformed the study of amyloid diseases. Filaments were extracted from parietal lobe tissue of the two affected individuals and their structures determined. Although tau paired helical filaments, the tangles that accompany most forms of Alzheimer’s disease, were present in the samples, the predominant filaments were built not from tau but from the amyloid-β peptide itself, specifically the Aβ40 species carrying the A21G substitution. The Flemish fold, it turned out, is written directly into the peptide sequence.

Structurally, the filaments are composed of two identical protofilaments, each spanning residues D1 through V40 of the amyloid-β peptide, packed together with two-start helical symmetry. This means that two protofilaments run in parallel along the length of the filament, twisting around each other in a helical arrangement. Comparative analysis revealed a striking continuity with previously known amyloid structures: the region of the peptide preceding the mutation site, residues Y10 through F19, adopts essentially the same substructure in both the Flemish fold and in wild-type Aβ42 filaments. The mutation’s effect is therefore not a wholesale remodeling of the peptide but a subtle yet consequential local change. The glycine substitution removes a single methyl group from residue 21, and the loss of that small hydrophobic moiety is enough to redirect the packing of the entire filament.

What emerges downstream of residue 21 is a completely different arrangement from all previously characterized Aβ folds. Since the first amyloid structures were determined, structural biologists have catalogued a growing repertoire of filament folds in Alzheimer’s disease and related disorders, each associated with different clinical presentations. The Flemish fold now joins this catalogue as a distinct entry, defined by its own hydrophobic interface, the interdigitating surface through which the two protofilaments and successive peptide layers stabilize one another. That an alteration of a single methyl group can generate a fold with no known counterpart underscores the exquisite sensitivity of amyloid assembly to sequence chemistry, and suggests that the growing library of familial APP mutations may each encode their own structural signatures.

The structural work alone could not explain why the Flemish fold associates with blood vessels. To address that question, the researchers employed a cell-based assay, and their results provide the study’s most intriguing mechanistic clue. The distinctive Flemish fold was found to be associated with the vascular tropism characteristic of this variant. In other words, the particular architecture of the filament, dictated by the A21G substitution, correlates with the propensity of amyloid to deposit in vessel walls rather than, or in addition to, the brain parenchyma. Cerebral amyloid angiopathy arises when amyloid-β, particularly the Aβ40 species, accumulates within the smooth muscle and basement membrane of leptomeningeal and cortical arteries, weakening them until they rupture. The Flemish findings now provide a structural vocabulary for that process: a fold that appears optimized, in some sense, for the vascular environment.

The implications extend beyond a single family. Dominantly inherited mutations in APP and in the presenilin genes have long served as guideposts for understanding Alzheimer’s disease more broadly, on the logic that if a mutation is sufficient to cause the disease, the pathway it disrupts must be central to the illness. The identification of a mutation-specific filament fold strengthens an increasingly influential idea in the field: that amyloid polymorphism, the existence of distinct filament structures, may correspond to distinct disease phenotypes. Previous cryo-EM studies have shown that different folds correlate with different dementias, including variants of Alzheimer’s disease and cerebral amyloid angiopathy with differing clinical courses. The Flemish fold, being tied to a specific pedigree and a specific clinical syndrome, offers one of the cleanest demonstrations yet that structure and phenotype are mechanistically linked.

The rarity of the Flemish pedigrees makes the achievement particularly notable. Only two such families are known worldwide, and obtaining postmortem brain tissue from affected members is exceptionally difficult. The fact that filaments from two independent individuals yielded consistent structures, with Aβ40-A21G as the predominant component, provides confidence that the Flemish fold is a reproducible biological entity rather than an artifact of a single brain. The presence of tau paired helical filaments alongside the amyloid filaments also confirms that the Flemish variant produces a bona fide Alzheimer-type pathology, complete with both plaques and tangles, even as its vascular features set it apart.

For the molecular understanding of Flemish-type dementia and cerebral hemorrhage, the study delivers what its authors describe as the definition of a familial Alzheimer-disease-associated amyloid fold. This framing matters because it establishes the Flemish fold as a structural unit of analysis in its own right. Future work can now ask mechanistic questions at atomic resolution: how the hydrophobic interface of the Flemish fold interacts with vascular basement membranes, whether the fold nucleates more readily on vascular surfaces, whether the faster clearance of Aβ40 from brain tissue funnels the peptide into vessels, and whether small molecules could be designed to destabilize the Flemish fold specifically. The loss of a single methyl group at residue 21, and the filament architecture it produces, has gone from a genetic curiosity to a defined structural target.

More broadly, the work exemplifies the maturing relationship between cryo-EM and neurodegenerative disease research. In the space of a decade, amyloid structures have progressed from generic models to fold-specific structures that distinguish diseases, mutations, and even individual patients. Each new fold added to the catalogue is a potential biomarker, a phenotypic explanation, and a drug-discovery template all at once. The Flemish fold demonstrates that even in a disease as intensively studied as Alzheimer’s, the structural landscape remains incompletely mapped, and that rare families, however small in number, can illuminate molecular mechanisms invisible in the common sporadic form of the illness. For the members of the two Flemish pedigrees and for the broader effort to understand cerebral hemorrhage in Alzheimer’s disease, the structure now provides a foundation on which diagnostic, mechanistic, and therapeutic advances can be built, one methyl group at a time.

Lysosomes are often described as the recycling centers of the cell. These acidic, membrane-bound compartments contain a cocktail of degradative enzymes capable of breaking down proteins, lipids, damaged organelles, and other cellular debris into their basic building blocks, which can then be reused. Because nearly every cellular waste stream ultimately passes through the lysosome, even partial impairment of these organelles can cascade into widespread dysfunction. Lysosomal damage is a hallmark of aging, neurodegenerative disease, and ischemia-reperfusion injury, the tissue damage that occurs when blood supply returns to tissue after a period of oxygen deprivation. Yet despite decades of research into lysosome biology, the mechanisms that maintain lysosomal integrity under stress have remained incompletely understood.

The prevailing models of lysosomal maintenance have centered on autophagic lysosome reformation, a process in which lysosomal components are salvaged from autolysosomes, hybrid compartments formed when autophagosomes fuse with lysosomes, and reassembled into new functional lysosomes. The new study demonstrates that B-fission operates independently of this canonical pathway. When lysosomes are damaged by hypoxia-reoxygenation stress, they do not simply wait to be recycled through autophagy. Instead, they actively participate in their own rescue, generating membrane buds on their surface. These buds progressively extend from the parent organelle and then undergo scission, pinching off to yield small, fully functional lysosomes. The undamaged components of the impaired parent organelle are thereby reorganized into daughter organelles, leaving the damaged material behind to be dealt with separately.

The mechanistic heart of the discovery lies in the identity of the scission machinery. Budding and fission events in cells generally require a specific set of proteins to constrict and sever a membrane neck. For mitochondria, that machinery is well known: the dynamin-related GTPase DRP1, recruited to the mitochondrial outer membrane by adaptor proteins such as MFF, constricts and divides mitochondria during mitochondrial fission. The researchers found that damaged lysosomes co-opt this exact mitochondrial division apparatus. MFF, a fission adaptor normally resident on mitochondria, is delivered to lysosomes, where it recruits DRP1 to drive the scission of the budding lysosomal membrane. In other words, the cell repurposes the mitochondrial division machinery to divide a completely different organelle.

How does MFF get to lysosomes in the first place? The answer involves mitochondrial-derived vesicles, or MDVs. These small vesicles bud from mitochondria and are known to transport selected mitochondrial cargo to other cellular destinations, most notably to peroxisomes and to autophagosomes during mitophagy. The new work shows that under hypoxia-reoxygenation stress, mitochondria generate MDVs carrying MFF. These MFF-positive vesicles then travel to damaged lysosomes and deliver their cargo, providing the adaptor that lysosomes need to assemble a functional DRP1-dependent scission apparatus. This is a striking example of organelle-to-organelle communication, with mitochondria effectively supplying the tools that allow lysosomes to renew themselves.

Two additional proteins complete the regulatory circuit. The first is MIRO2, a mitochondrial outer-membrane GTPase better known for its role in linking mitochondria to microtubule-dependent motor proteins and regulating mitochondrial motility. The study shows that MIRO2 promotes the formation of MFF-positive MDVs through a direct physical interaction with MFF, acting as a gatekeeper that selects MFF as cargo for vesicular export. The second is ITM2C, a lysosomal membrane protein that binds MIRO2. By tethering the MFF-carrying vesicles to the lysosomal surface, ITM2C guides and anchors them at the correct destination, ensuring efficient MFF delivery and, consequently, efficient B-fission. The researchers describe this stress-responsive pathway as the ITM2C–MIRO2–MFF–DRP1 axis, a chain of interactions that connects the mitochondrial surface to the lysosomal scission machinery.

The physiological relevance of this pathway was demonstrated through manipulation of AMPK, the AMP-activated protein kinase, a master metabolic sensor that is activated when cellular energy levels fall. When cells were treated with AMPK activators such as 991 or metformin under normal oxygen conditions, MFF-dependent lysosomal B-fission was promoted, indicating that AMPK is a physiological trigger for the pathway. Conversely, when AMPK was inhibited with dorsomorphin during hypoxia-reoxygenation, B-fission was suppressed, and lysosomes presumably remained in their damaged state. This pharmacological control establishes AMPK as a central node that couples energy stress to lysosomal renewal, and it raises the intriguing possibility that widely used drugs such as metformin may partially exert their protective effects by boosting this lysosome-repair program.

The implications of the work extend across multiple fields. For researchers studying ischemia-reperfusion injury, the identification of a stress-activated lysosomal renewal pathway offers a mechanistic explanation for why lysosomal damage is so consequential during heart attack and stroke, and it suggests that enhancing B-fission pharmacologically could protect vulnerable tissues. For the lysosome biology community, the finding adds a new mode of organelle maintenance to the established repertoire of autophagic lysosome reformation and endosomal sorting. And for cell biologists more broadly, the demonstration that MDVs can ferry a fission adaptor between organelles, and that a mitochondrial division machine can be installed on lysosomes, underscores how fluid the boundaries between organelle systems really are. Mitochondria, long appreciated as signaling hubs that communicate through calcium, reactive oxygen species, and metabolites, now appear to communicate through physical transport of division machinery as well.

The technical elegance of the study lies in its dissection of each step of the pathway. By showing that MIRO2 binds MFF directly, that MDVs carry MFF, that ITM2C tethers those vesicles to lysosomes, and that DRP1 recruitment to MFF-decorated lysosomes is required for scission, the authors built a complete causal chain from mitochondrial membrane to lysosomal division. Disrupting any single link, whether by removing MIRO2, ITM2C, MFF, or DRP1, or by blocking AMPK signaling, compromises the ability of stressed cells to regenerate functional lysosomes from damaged parents. Conversely, activating AMPK under baseline conditions is sufficient to initiate the program even without hypoxic stress.

What remains to be explored is the breadth of this phenomenon. Hypoxia-reoxygenation is a particularly well-defined stress, but lysosomal damage arises in many contexts, including exposure to aggregate-prone proteins in neurodegeneration, lipid overload in metabolic disease, and the normal wear of aging. Whether B-fission operates in neurons, in cardiomyocytes, and in aging tissues in vivo are pressing questions. There is also the tantalizing therapeutic prospect that metformin, already one of the most prescribed drugs in the world, could be repurposed or optimized to strengthen lysosomal quality control in diseases of lysosomal stress. For now, the study stands as a vivid demonstration that the cell’s repair strategies are more inventive than previously imagined: when a lysosome is damaged, the mitochondria deliver the scissors that let it cut its losses and begin again.

Proteins are long chains of amino acids that must fold into precise three-dimensional structures before they can perform their functions. This folding process is governed by a complex balance of chemical forces, including hydrogen bonding, hydrophobic interactions, electrostatic attraction and the movement of water around the protein surface. A small change in temperature, pH, genetic sequence or chemical environment can destabilize that balance. When a protein fails to maintain its native structure, it may partially unfold and expose normally hidden regions. These exposed surfaces can interact with equivalent regions on other molecules, allowing the proteins to associate into oligomers, fibers and eventually amyloid deposits. Such assemblies are central features of several neurodegenerative and cardiovascular diseases, but their formation is not a simple chemical accident. It is a dynamic process that can potentially be redirected with carefully designed molecules.

Kelly’s research has focused on understanding that process at a level detailed enough to reveal where therapeutic intervention is possible. His laboratory has combined organic chemistry, biophysics, structural biology and cell-based approaches to examine how proteins move between folded, unfolded and aggregated states. Rather than viewing misfolding as a single catastrophic event, the work has treated it as an energy landscape containing multiple intermediate forms. Some intermediates may be short-lived and harmless, while others can act as especially efficient seeds for further aggregation. Identifying which molecular states initiate disease is essential because a treatment may need to stabilize the healthy protein before it begins to unravel, block the formation of toxic intermediates or prevent already formed assemblies from damaging cells. This framework has helped shift protein-misfolding research from observation toward rational therapeutic design.

One of Kelly’s most influential achievements involved transthyretin, or TTR, a protein produced primarily by the liver and responsible for transporting thyroxine and retinol-binding protein in the bloodstream. TTR normally circulates as a tetramer made of four identical subunits. In hereditary forms of transthyretin amyloidosis, mutations can weaken the interactions holding the tetramer together. The complex may then dissociate into individual subunits, which can partially unfold and assemble into amyloid fibrils. These fibrils accumulate in tissues, damaging peripheral nerves in transthyretin amyloid polyneuropathy and impairing the structure and function of the heart in transthyretin amyloid cardiomyopathy. Even the normal, nonmutated protein can become amyloidogenic with age, making the disease relevant beyond inherited mutations. Kelly’s studies clarified that tetramer destabilization is a critical early event and therefore a promising point for intervention.

That mechanistic insight contributed to the development of tafamidis, the active pharmaceutical ingredient in Vyndamax and Vyndaqel, medicines approved by the U.S. Food and Drug Administration for transthyretin-related disease. Tafamidis functions as a kinetic stabilizer: it binds to thyroxine-binding sites within the TTR tetramer and makes dissociation less likely. The distinction between thermodynamic and kinetic stabilization is important. A drug does not necessarily need to make the folded state the only energetically favorable state; it can instead slow the rate at which the protein reaches a disease-associated state, extending the lifetime of the functional tetramer. By reducing the supply of misfolded TTR subunits, the treatment can limit the production of new amyloid material. The approach demonstrates how defining the molecular sequence of disease can reveal a practical treatment strategy that operates before irreversible tissue damage becomes extensive.

The development of TTR stabilizers also illustrates why protein aggregation cannot be addressed solely by searching for compounds that dissolve visible deposits. Amyloid fibrils may represent the endpoint of a much longer process, and the most harmful species can arise earlier, when small assemblies interact with cell membranes or disrupt intracellular pathways. A drug that targets the earliest destabilizing transition may therefore have greater impact than one aimed at mature deposits. Kelly’s research helped establish this preventive logic by linking the behavior of individual protein molecules to disease progression in patients. It also provided a general model for studying other amyloid disorders, in which the identities of the proteins differ but the underlying challenges—conformational instability, intermolecular association and tissue-specific toxicity—are conceptually related. The work has made protein chemistry a direct engine of therapeutic discovery.

The European Academy of Engineering, founded in Sweden in 1992, brings together experts from a broad range of technical disciplines and advises on issues involving policy, public health and education. Its members are elected by peers across 13 engineering classes, each representing a specialized area. Kelly’s election recognizes a career in which discoveries traditionally associated with chemistry have produced consequences for biomedical engineering, drug development and clinical care. His honors include the Canada Gairdner International Award, election to the U.S. National Academy of Sciences, the Wolf Prize in Chemistry in 2023 and the Breakthrough Prize in Life Sciences in 2022, in addition to numerous other distinctions. Together, these awards reflect the unusual reach of research that began with questions about molecular structure and ultimately helped produce a medicine for a life-threatening protein-aggregation disorder.

Kelly’s election arrives as scientists increasingly seek therapies that modify the physical behavior of disease-linked proteins rather than merely treating symptoms after damage has occurred. Advances in cryo-electron microscopy, nuclear magnetic resonance, mass spectrometry and computational modeling are making it possible to observe unstable conformations and transient protein assemblies with growing precision. These tools may reveal additional opportunities to stabilize vulnerable proteins, remove harmful species or correct the cellular systems responsible for protein quality control. The broader lesson of Kelly’s work is that understanding how a protein fails can be as important as understanding how it functions when healthy. By tracing the molecular steps that connect folding errors to human disease, researchers can convert a seemingly microscopic chemical event into a clear therapeutic target—and, in some cases, into a treatment capable of changing the course of illness.

Subject of Research: Protein folding, protein misfolding and amyloid aggregation, with a focus on transthyretin amyloidosis and therapeutic protein stabilization.

Web References: Jeffery Kelly — Scripps Research

Image Credits: Scripps Research

Keywords

Protein folding; neurodegenerative diseases; cardiomyopathy; transthyretin amyloidosis; amyloid aggregation; protein misfolding; biomedical engineering; tafamidis; Scripps Research; Jeffery Kelly

The word “ephaptic” refers to electrical interaction that occurs outside the specialized junctions formed by chemical or electrical synapses. When a neuron fires, currents flow along its membrane and through the surrounding extracellular space. Those currents alter the local extracellular potential, and nearby neurons can detect the resulting change because a neuron’s effective electrical state depends on the voltage difference between its interior and its surroundings. In simplified terms, if the extracellular voltage near a neighboring neuron shifts, the transmembrane voltage—the quantity that determines whether the cell moves toward or away from firing—also changes. The effect is usually subtle, but when many cells are densely packed, aligned in parallel or firing together, these small perturbations can accumulate and influence network behavior.

The mathematical models reviewed in the study span a wide range of complexity. At one end are phenomenological systems that reduce each neuron to a small number of variables, representing such features as membrane voltage, recovery processes and firing thresholds. These models are computationally efficient and can simulate large populations, making them useful for studying synchronization and collective rhythms. Quadratic integrate-and-fire models with ephaptic coupling, for example, describe neurons through simplified voltage dynamics while adding terms that represent the influence of an extracellular field. Although such models omit many biological details, they can reveal how weak electrical interactions alter the timing of spikes across thousands or millions of cells.

At the other end are biophysically detailed models based on cable theory and conductance-based descriptions of neuronal membranes. These frameworks divide an axon or dendrite into spatial compartments and calculate how electrical signals move through each segment. They can incorporate voltage-gated sodium and potassium channels, membrane capacitance, intracellular resistance and the geometry of the extracellular environment. Some models distinguish between myelinated and unmyelinated fibers, account for axonal diameter and represent the irregular placement of nodes of Ranvier, the exposed membrane regions where action potentials are regenerated. By including these features, researchers can ask whether ephaptic effects are amplified at specific anatomical structures or under particular patterns of neuronal activity.

A central technical challenge is determining how the extracellular field should be calculated. In the simplest approaches, the field is approximated by assuming that neurons are embedded in a uniform conductive medium. More advanced simulations solve the electrical interactions between extracellular and intracellular spaces directly. Extracellular–membrane–intracellular, or EMI, models describe the geometry of cells and the surrounding medium together, allowing researchers to examine how currents are redistributed near membranes. Kirchhoff–Nernst–Planck models go further by representing ionic movement, electric forces and concentration gradients. These approaches are computationally demanding, but they may become essential when ephaptic coupling is linked to changes in extracellular sodium, potassium or other ion concentrations.

The review highlights why ephaptic coupling is attracting attention in studies of synchronization. Conventional synaptic communication typically introduces delays, nonlinear chemical transformations or specific connection patterns. Ephaptic interactions, by contrast, can influence nearby cells almost instantaneously through the shared electric environment. A neuron’s extracellular field may slightly advance or delay the firing of another neuron, and repeated interactions can align spike timing. In a densely organized bundle of axons, this feedback may create a form of electrical cooperation: synchronized activity strengthens the local field, which in turn makes further synchronization more likely. The result could help explain some population-level rhythms observed in electroencephalography, electrocorticography and local field-potential recordings.

The same mechanism may also affect how nervous systems encode sensory information. Sensory pathways often contain tightly packed, similarly oriented fibers in which electrical fields can spread efficiently. A stimulus that activates many neighboring axons could therefore modify the timing and reliability of signals without changing the chemical synapses connecting those neurons. Small shifts in spike timing can carry important information, particularly in systems that use temporal coding. Mathematical models allow researchers to test whether ephaptic effects sharpen a population response, broaden it, create phase alignment or alter the threshold at which a stimulus becomes detectable. These predictions can then be compared with recordings from peripheral nerves, sensory circuits and cortical tissue.

Pathology provides another reason to take the phenomenon seriously. In epilepsy, large populations of neurons become excessively synchronized, producing abnormal electrical discharges that can spread through the brain. The reviewed models suggest that extracellular fields may participate in this process, either by reinforcing synchronization or by changing the conditions under which a seizure propagates. Demyelination could have especially important consequences because myelin normally insulates axons and shapes the distribution of current. When that insulation is damaged, current may leak into the extracellular space, potentially increasing unintended interactions between neighboring fibers. Such effects could contribute to conduction abnormalities in disorders such as multiple sclerosis, although the precise role of ephaptic coupling remains an active research question rather than a settled clinical explanation.

The review also connects ephaptic modeling with questions about neuropathic pain and neurodegeneration. Damage to axons, changes in membrane structure and altered ion concentrations can all modify the electrical environment around neurons. If injured fibers become more excitable or electrically exposed, neighboring fibers might be recruited in abnormal ways, potentially contributing to spontaneous activity or distorted sensory signals. In neurodegenerative conditions, the loss of tissue organization and changes in extracellular space may likewise reshape field-mediated interactions. The models do not establish that ephaptic coupling is the primary cause of these diseases, but they offer a way to investigate mechanisms that conventional synaptic diagrams may overlook.

By cataloguing the available models, their assumptions, tested hypotheses and open-source implementations, Kondrakhin and his colleagues aim to make the field easier to navigate. The review emphasizes that no single model can capture every level of ephaptic biology. Simplified equations are indispensable for exploring large networks and identifying general principles, while detailed simulations are needed to test how morphology, ion dynamics and tissue geometry shape the effect in real neurons. The next phase of research will likely depend on linking these approaches with experimental measurements of extracellular potentials, axonal structure and ionic composition. If that integration succeeds, ephaptic coupling could become more than a specialized theoretical concept: it could emerge as a measurable component of how neural circuits synchronize, compute and fail.

Subject of Research: Mathematical models of ephaptic coupling between neurons

Article Title: Ephaptic coupling between neurons: a systematic review of mathematical models

Article References: Kondrakhin, P.Y., Dubrovin, S.V., Chupov, E.A. et al. “Ephaptic coupling between neurons: a systematic review of mathematical models.” BMC Bioinformatics (2026).

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06618-6

Keywords: Ephaptic coupling, mathematical modeling, neuronal synchronization, extracellular electric fields, epilepsy, demyelination, neuropathic pain, neurodegeneration, computational neuroscience

The research focuses on N⁶-methyladenosine, commonly called m⁶A, the most abundant internal chemical modification found on messenger RNA in mammalian cells. Messenger RNA carries genetic instructions from DNA to the cellular machinery that produces proteins. By adding or removing m⁶A marks, cells can influence how long an RNA molecule survives, how efficiently it is translated into protein, and how it is processed. These changes help cells respond rapidly to stress, infection, and inflammation. However, when m⁶A regulation becomes unbalanced, the same system may contribute to persistent disease-related signaling.

METTL3 is one of the central enzymes responsible for installing m⁶A marks on RNA. It works as part of a larger molecular complex, often referred to as the m⁶A writer machinery. Previous studies have connected abnormal METTL3 activity with immune-cell activation, cancer biology, and inflammatory responses in the nervous system. Because METTL3 can influence the expression of numerous genes at once, directly altering its activity could potentially reshape entire inflammatory programs. The challenge is delivering such an intervention to the right tissues while avoiding unwanted effects elsewhere in the body.

To address that challenge, the investigators used engineered nanovesicles. These nanoscale particles are enclosed by lipid membranes and can be designed to transport biological or chemical cargo into target cells. Nanovesicles are attractive for neurological applications because their size and surface properties can be adjusted to influence tissue distribution, cellular uptake, and interactions with biological barriers. In this study, the vesicles were configured to target the METTL3 pathway, allowing the researchers to test whether a localized molecular intervention could dampen inflammatory signaling more selectively than a conventional systemic drug.

The researchers examined the effects of the METTL3-targeting nanovesicles in vitro, using cultured cells to observe how the treatment affected inflammatory responses under controlled conditions. Such experiments can reveal whether the engineered particles enter cells, whether they alter the intended RNA-regulatory pathway, and whether inflammatory molecules decline after treatment. The study’s central observation was that targeting METTL3 with the engineered vesicles reduced indicators of neuroinflammation in these laboratory systems. This suggests that the RNA-modification machinery is not merely associated with inflammation but may be therapeutically actionable.

The work also extended beyond cell cultures into in vivo models, an important step because the brain’s immune environment is shaped by complex interactions among neurons, astrocytes, microglia, blood vessels, and infiltrating immune cells. Microglia, the resident immune cells of the central nervous system, can shift between protective and damaging states depending on the signals they receive. Excessive or prolonged activation can release cytokines, chemokines, and other mediators that disrupt neuronal function and damage surrounding tissue. According to the report, the nanovesicle-based METTL3 intervention reduced neuroinflammatory responses in living organisms, indicating that the platform can function within a more complex biological environment.

The findings are particularly relevant to emerging research on viral neuroinflammation. Some viruses that infect or affect the nervous system can trigger immune reactions that continue after the initial pathogen burden has fallen. In these situations, tissue damage may result not only from viral replication but also from an immune response that becomes poorly controlled. RNA modifications such as m⁶A are already known to influence interactions between host cells and viruses, including viral RNA stability, replication, and immune recognition. A delivery system that adjusts METTL3 activity could therefore become useful for investigating how inflammatory responses develop during viral or post-viral neurological disease, although the present study does not establish a treatment for any specific infection.

The approach remains experimental, and several questions will need to be answered before it can move toward clinical testing. Researchers must determine how precisely the nanovesicles distribute through the brain, how long their effects last, and whether repeated administration causes toxicity or immune reactions. It will also be necessary to define which RNA transcripts are altered after METTL3 targeting and to distinguish beneficial suppression of inflammation from interference with normal immune surveillance. Because m⁶A regulation affects many cellular processes, dose, timing, and tissue specificity will be critical factors in future development.

Even with these limitations, the study highlights a convergence of two rapidly advancing fields: epitranscriptomics, which examines chemical marks on RNA, and nanomedicine, which seeks to deliver therapies with greater precision. By combining a molecular target involved in gene regulation with a vehicle engineered for cellular delivery, the researchers offer a framework for treating neuroinflammation at the level of its regulatory circuitry. The results do not yet demonstrate effectiveness in human disease, but they provide evidence that METTL3-directed nanovesicles could become a platform for future investigations into inflammatory neurological disorders, including conditions in which viral infection and immune-mediated damage overlap.

Subject of Research: Engineered nanovesicles targeting the m⁶A writer METTL3 to reduce neuroinflammation in vitro and in vivo.

Article Title: Targeting m⁶A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo.

Article References: Xu, L., Pan, Y., Li, G. et al. Targeting m⁶A writer METTL3 with engineered nanovesicles reduces neuroinflammation in vitro and in vivo. Nature Communications (2026). https://doi.org/10.1038/s41467-026-75862-4

Image Credits: AI Generated

DOI: 10.1038/s41467-026-75862-4

Keywords: Neuroinflammation, METTL3, m⁶A RNA modification, engineered nanovesicles, epitranscriptomics, nanomedicine, neuroimmunology, viral neuroinflammation

Neurons possess a limited intrinsic ability to store and detoxify lipids, rendering them heavily reliant on astrocytes to maintain lipid homeostasis. This dependency places astrocytes at the frontline of protecting neurons from lipid-induced toxicity. Importantly, Kim and Halliday’s review underscores that disruptions in astrocytic lipid metabolism are among the earliest detectable events preceding neuronal degeneration in numerous neurodegenerative disorders.

Conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal dementia, and Huntington’s disease have all been linked to significant perturbations in astrocytic lipid handling. When the lipid regulatory functions of astrocytes become compromised, this leads to maladaptive reactive states. These states exacerbate oxidative stress, impair organelle functions—particularly lysosomes and mitochondria—and disturb the critical lipid exchange between neurons and glia, cumulatively fostering a neurotoxic milieu conducive to degeneration.

The mechanistic insights presented by Kim and Halliday reveal that astrocytic lipid dysregulation is not merely a passive consequence of neurodegeneration but might act as an instructive, early driver of neuronal vulnerability. Contrary to being categorically protective or pathological, astrocytic lipid metabolism plays nuanced physiological roles that, when disrupted, can tip the balance toward disease.

This paradigm shift implicates astrocytes as promising therapeutic targets. By restoring or modulating lipid homeostasis within these glial cells, it may be possible to halt or delay the progression of neurodegenerative diseases. Beyond treatment, understanding astrocyte lipid dynamics opens new avenues for early biomarker detection, offering the potential for pre-symptomatic diagnosis.

The review critically differentiates between correlative findings and causal pathways, advocating for more targeted studies to unravel the precise molecular mechanisms by which astrocytic lipid dysregulation triggers neuronal compromise. This insight challenges previously neuron-centric models of neurodegeneration and suggests that glia-centered interventions could revolutionize clinical approaches.

Ultimately, the emerging evidence positions astrocytes as central players in neurological health, emphasizing the need to reconsider their role in the etiology of neurodegenerative diseases. By focusing on the metabolic underpinnings governed by astrocytes, researchers may unlock novel strategies for diagnosis, intervention, and possibly prevention of some of the most devastating brain disorders.

Subject of Research: Astrocytic lipid metabolism and its role in neurodegeneration

Article Title: Astrocytic lipid dysregulation as an early driver of neurodegeneration

Article References:
Kim, W.S., Halliday, G.M. Astrocytic lipid dysregulation as an early driver of neurodegeneration. Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01238-3

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01238-3

Keywords: Astrocytes, lipid metabolism, neurodegeneration, oxidative stress, cholesterol synthesis, reactive astrocytes, neurodegenerative diseases